SCHEMBL3756414

SCHEMBL3756414

CCOC(=O)c1c(-c2ccccc2)csc1NC(=O)C12CC3CC(CC1C3)C2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.64
LMNA P02545 10/20 0.58
GSTO1 P78417 1/20 0.58
ALDH1A1 P00352 9/20 0.57
SMN1; SMN2 Q16637 8/20 0.57
MAPT P10636 7/20 0.57
MEN1 O00255 6/20 0.57
KMT2A Q03164 6/20 0.57
ALOX12 P18054 3/20 0.57
HTT P42858 2/20 0.57
POLB P06746 4/20 0.56
RAB9A P51151 1/20 0.56
KDM4E B2RXH2 3/20 0.56
HPGD P15428 3/20 0.56
NPSR1 Q6W5P4 2/20 0.56
PTPN1 P18031 3/20 0.56
PTPRC P08575 1/20 0.56
PTPRF P10586 1/20 0.56
PTPN2 P17706 1/20 0.56
PTPA Q15257 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4095706 0.87 TP53 (0.64) CNR2LMNAALDH1A1SMN1; SMN2MAPT
SCHEMBL4084850 0.86 L3MBTL1 (0.56) CNR2LMNAGSTO1ALDH1A1SMN1; SMN2
SCHEMBL4091492 0.86 CNR2 (0.62) CNR2LMNAALDH1A1SMN1; SMN2MAPT
SCHEMBL3801843 0.86 CNR2 (0.62) CNR2LMNAALDH1A1SMN1; SMN2MAPT
SCHEMBL4084849 0.85 CNR2 (0.51) CNR2ALDH1A1MAPTMEN1KMT2A
SCHEMBL3797476 0.85 CNR2 (0.51) CNR2ALDH1A1MAPTMEN1KMT2A
SCHEMBL4080614 0.84 CNR2 (0.57) CNR2LMNAGSTO1ALDH1A1SMN1; SMN2
SCHEMBL4085846 0.81 MAPK8 (0.56) CNR2LMNAALDH1A1SMN1; SMN2MAPT
SCHEMBL3813611 0.81 MAPK8 (0.56) CNR2LMNAALDH1A1SMN1; SMN2MAPT
SCHEMBL4080526 0.80 MAPK8 (0.52) CNR2LMNAALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338623-B2 N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBVIE INC. (US) 2012-12-25 US disclosed
EP-2176219-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS Abbott Laboratories (US) 2010-04-21 EP disclosed
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-01-15 US disclosed
WO-2009009550-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 CNR2 2/4885LMNA 3611/4885GSTO1 4290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.